🍽️ cloperastine hydrochloride,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Cough Suppression: Cloperastine hydrochloride is used to alleviate cough symptoms associated with respiratory conditions such as the common cold, influenza, bronchitis, sinusitis, and allergies. It works by suppressing the cough reflex in the central nervous system, thereby reducing the frequency and intensity of coughing episodes. Cloperastine hydrochloride is particularly effective in managing non-productive or dry coughs, where there is no significant mucus production.

  2. Antitussive Activity: Cloperastine hydrochloride acts centrally in the brain to inhibit the cough reflex, rather than directly affecting the respiratory tract. It exerts its antitussive effects by binding to sigma-1 receptors and blocking the transmission of cough signals along the cough reflex pathway. This mechanism of action distinguishes cloperastine hydrochloride from other cough suppressants, such as opioids or expectorants, which may have different modes of action or side effect profiles.

  3. Efficacy: Cloperastine hydrochloride has been shown to be effective in reducing cough frequency and severity in clinical studies and trials involving patients with various respiratory conditions. It is often used as a symptomatic treatment to provide relief from bothersome cough symptoms while underlying respiratory infections or conditions resolve. Cloperastine hydrochloride may be used alone or in combination with other medications, depending on the nature and severity of the cough.

  4. Safety and Tolerability: Cloperastine hydrochloride is generally well-tolerated by most individuals when used at recommended doses. Common side effects may include drowsiness, dizziness, headache, gastrointestinal upset (such as nausea or vomiting), dry mouth, and allergic reactions (such as skin rash or itching). These side effects are usually mild and transient, resolving with continued use or upon discontinuation of the medication. Serious adverse reactions to cloperastine hydrochloride are rare but may include hypersensitivity reactions or respiratory depression in susceptible individuals.

  5. Dosage and Administration: Cloperastine hydrochloride is available in various oral formulations, including tablets, capsules, syrups, and lozenges, for administration according to the age and weight of the patient. The dosage and frequency of cloperastine hydrochloride therapy depend on factors such as the severity of cough symptoms, the patient's age and medical condition, and the specific formulation used. Patients should follow the instructions provided by their healthcare provider or medication label for proper dosing and administration.

  6. Contraindications and Precautions: Cloperastine hydrochloride is contraindicated in individuals with known hypersensitivity to cloperastine or any of its components. It should be used with caution in patients with impaired renal or hepatic function, respiratory disorders (such as asthma or chronic obstructive pulmonary disease), or a history of substance abuse or addiction. Cloperastine hydrochloride may interact with other medications, particularly central nervous system depressants or monoamine oxidase inhibitors (MAOIs), increasing the risk of adverse effects or drug interactions.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of cloperastine hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces

Bacteria Impacted by cloperastine hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Phocaeicola genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Bacteroides genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Roseburia genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Blautia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Lachnospira eligens species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Bilophila wadsworthia species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Agathobacter rectalis species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
[Ruminococcus] gnavus species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Blautia obeum species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of cloperastine hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
ADHD 1.8 0 0
Age-Related Macular Degeneration and Glaucoma 0.3 0.2 0.5
Allergic Rhinitis (Hay Fever) 0.8 0.8
Allergies 0.9 1.2 -0.33
Allergy to milk products 0.3 0.2 0.5
Alopecia (Hair Loss) 0.9 0.9
Alzheimer's disease 1.7 3.4 -1
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.5 0.6 3.17
Ankylosing spondylitis 1.7 1 0.7
Anorexia Nervosa 0.2 1.4 -6
Antiphospholipid syndrome (APS) 1 0.3 2.33
Asthma 1.4 -1.4
Atherosclerosis 0.1 1 -9
Atrial fibrillation 1.5 1.5 0
Autism 4.2 6.5 -0.55
Barrett esophagus cancer 0.1 -0.1
Bipolar Disorder 0.9 0.3 2
Brain Trauma 0.1 0.6 -5
Carcinoma 1.1 0.7 0.57
Celiac Disease 1.4 1.7 -0.21
Cerebral Palsy 0.4 0.6 -0.5
Chronic Fatigue Syndrome 2.2 2.5 -0.14
Chronic Kidney Disease 0.8 1.4 -0.75
Chronic Lyme 0.6 -0.6
Chronic Obstructive Pulmonary Disease (COPD) 0.3 0.7 -1.33
Chronic Urticaria (Hives) 0.1 1.9 -18
Coagulation / Micro clot triggering bacteria 0.4 0.4 0
Colorectal Cancer 1.7 0.4 3.25
Constipation 1.8 0.3 5
Coronary artery disease 0.6 0 0
COVID-19 3.5 7.7 -1.2
Crohn's Disease 3.4 3.9 -0.15
cystic fibrosis 0.6 -0.6
deep vein thrombosis 0.4 -0.4
Depression 5.1 3.1 0.65
Dermatomyositis 0.1 0.1
Eczema 0.2 1.1 -4.5
Endometriosis 0.7 0.5 0.4
Epilepsy 1.5 1.6 -0.07
Fibromyalgia 1.1 1.9 -0.73
Functional constipation / chronic idiopathic constipation 3.2 1.9 0.68
gallstone disease (gsd) 0.3 0.2 0.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.7 0.2 7.5
Generalized anxiety disorder 0.2 0.3 -0.5
Glioblastoma 0.1 -0.1
Gout 0 0
Graves' disease 0.6 0.4 0.5
Halitosis 0.3 0.1 2
Hashimoto's thyroiditis 0.9 0.7 0.29
Hidradenitis Suppurativa 0.5 0.5
Histamine Issues,Mast Cell Issue, DAO Insufficiency 1.8 0.4 3.5
hypercholesterolemia (High Cholesterol) 0.6 -0.6
hyperglycemia 1.4 -1.4
Hyperlipidemia (High Blood Fats) 0.4 0.1 3
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 1 2 -1
Hypothyroidism 0 0
Hypoxia 0.8 0.8
IgA nephropathy (IgAN) 3.2 -3.2
Inflammatory Bowel Disease 2.1 5.6 -1.67
Insomnia 0.5 1 -1
Intelligence 1 0.6 0.67
Intracranial aneurysms 0.6 0.1 5
Irritable Bowel Syndrome 1.5 3.8 -1.53
Liver Cirrhosis 1.6 1.3 0.23
Long COVID 4.4 3.6 0.22
Low bone mineral density 0.7 -0.7
Lung Cancer 0.6 -0.6
ME/CFS with IBS 0.6 0.4 0.5
ME/CFS without IBS 0.4 1.2 -2
Metabolic Syndrome 2.7 4.8 -0.78
Mood Disorders 6 3.1 0.94
multiple chemical sensitivity [MCS] 0.6 0 0
Multiple Sclerosis 1.8 4.6 -1.56
Multiple system atrophy (MSA) 0.8 0 0
Neuropathy (all types) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.9 2 -1.22
Obesity 2.1 1.7 0.24
obsessive-compulsive disorder 3.9 2 0.95
Osteoarthritis 1.1 1.1
Osteoporosis 0.3 0.9 -2
pancreatic cancer 0.1 0.1
Parkinson's Disease 1.6 2.4 -0.5
Polycystic ovary syndrome 1.6 0.5 2.2
Postural orthostatic tachycardia syndrome 0 0
Premenstrual dysphoric disorder 0.1 0.2 -1
primary biliary cholangitis 0 1.1 0
Psoriasis 1.3 2.8 -1.15
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.1 1.4 1.21
Rosacea 0.2 -0.2
Schizophrenia 3 0.3 9
scoliosis 0 1.3 0
Sjögren syndrome 1 1.9 -0.9
Sleep Apnea 0 0.6 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.1
Stress / posttraumatic stress disorder 1.1 1.2 -0.09
Systemic Lupus Erythematosus 2 0.7 1.86
Tic Disorder 1 0.7 0.43
Tourette syndrome 0.3 0.3 0
Type 1 Diabetes 2.4 1.8 0.33
Type 2 Diabetes 3.7 4.9 -0.32
Ulcerative colitis 0.5 4.6 -8.2
Unhealthy Ageing 3.2 1.1 1.91

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.